Anemia in renal disease: Diagnosis and management

被引:75
作者
Lankhorst, Christina E. [2 ]
Wish, Jay B. [1 ]
机构
[1] Case Western Reserve Univ, Div Nephrol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA
[2] Univ Hosp Case Med Ctr, Div Nephrol, Cleveland, OH 44106 USA
关键词
Anemia; Chronic kidney disease; Erythropoietin; Erythropoiesis-stimulating agents; Ferritin; Transferrin saturation; Iron deficiency; Erythropoietin resistance; CHRONIC-KIDNEY-DISEASE; ERYTHROPOIESIS-STIMULATING AGENTS; LEFT-VENTRICULAR HYPERTROPHY; FUNCTIONAL IRON-DEFICIENCY; INTRAVENOUS ASCORBIC-ACID; QUALITY-OF-LIFE; EPOETIN-ALPHA; HEMODIALYSIS-PATIENTS; HEALTH-CARE; RESOURCE UTILIZATION;
D O I
10.1016/j.blre.2009.09.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic kidney disease (CKD) is a widespread health problem in the world and anemia is a common complication. Anemia conveys significant risk for cardiovascular disease, faster progression of renal failure and decreased quality of life. Patients with CKD can have anemia for many reasons, including but not invariably their renal insufficiency. These patients require a thorough evaluation to identify and correct causes of anemia other than erythropoietin deficiency. The mainstay of treatment of anemia secondary to CKD has become erythropoiesis-stimulating agents (ESAs). The use of ESAs does carry risks and these agents need to be used judiciously. Iron deficiency often co-exists in this population and must be evaluated and treated. Correction of iron deficiency can improve anemia and reduce ESA requirements. Partial, but not complete, correction of anemia is associated with improved outcomes in patients with CKD. (c) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:39 / 47
页数:9
相关论文
共 75 条
[1]  
Adams PC, 1997, HEPATOLOGY, V25, P162, DOI 10.1002/hep.510250130
[2]   Hyporesponsiveness to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: The Many Faces of Inflammation [J].
Adamson, John W. .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2009, 16 (02) :76-82
[3]  
*AMG INC, 2007, PROC EP ALF INJ PRES
[4]  
*AMG INC, 2007, EP EP ALF INJ PRES I
[5]  
*AMG INC, 2007, AR DARB ALF INJ PRES
[6]   Association of kidney function with anemia - The Third National Health and Nutrition Examination Survey (1988-1994) [J].
Astor, BC ;
Muntner, P ;
Levin, A ;
Eustace, JA ;
Coresh, J .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (12) :1401-1408
[7]   Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia [J].
Attallah, N ;
Osman-Malik, Y ;
Frinak, S ;
Besarab, A .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) :644-654
[8]   Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL [J].
Ayus, JC ;
Go, AS ;
Valderrabano, F ;
Verde, E ;
de Vinuesa, SG ;
Achinger, SG ;
Lorenzo, V ;
Arieff, AI ;
Luño, J .
KIDNEY INTERNATIONAL, 2005, 68 (02) :788-795
[9]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[10]   What Is So Bad About a Hemoglobin Level of 12 to 13 g/dL for Chronic Kidney Disease Patients Anyway? [J].
Besarab, Anatole ;
Frinak, Stanley ;
Yee, Jerry .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2009, 16 (02) :131-142